---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-22-010227"
form_type: "8-K"
ticker: "TGTX"
cik: "0001001316"
company_name: "TG THERAPEUTICS, INC."
filed_at: "2022-06-23T23:59:59+00:00"
generated_at: "2026-06-24T23:29:31.474311+00:00"
event_type: "other_material"
sentiment: "negative"
materiality_score: 0.35
calibrated_materiality_score: 0.15
confidence: "high"
source: SEC EDGAR
---

# TG Therapeutics shareholders reject advisory say-on-pay and annual frequency vote

## Summary
- Proposal 4 (advisory vote on executive compensation) defeated: 25.8M for, 61.2M against.
- Proposal 5 (advisory vote on frequency): 66.9M voted for annual, but board will retain triennial frequency.
- Director Yann Echelard and Daniel Hume each received only ~31.5% support, Sagar Lonial got 26.4%.
- Shareholders approved 2022 Incentive Plan (53.9M for, 33.3M against) and ratified KPMG (114.0M for).

## SEC filing metadata
- accession: 0001558370-22-010227
- form_type: 8-K
- ticker: TGTX
- cik: 0001001316
- company_name: TG THERAPEUTICS, INC.
- filed_at: 2022-06-23T23:59:59+00:00
- event_type: other_material
- sentiment: negative
- materiality_score: 0.35
- calibrated_materiality_score: 0.15
- confidence: high
- sec_items: 5.07, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1001316/000155837022010227/0001558370-22-010227-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1001316/000155837022010227/tgtx-20220616x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-22-010227
- JSON: https://secwatch.observer/filing/0001558370-22-010227.json
- Plain text: https://secwatch.observer/filing/0001558370-22-010227.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.